SNBL USA has received a response from the FDA indicating that SNBL has remedied process deficiencies specified in a September 2011 warning letter. “All remaining reporting requirements will be finished quickly,” said Dr. Thomas Beck, president and chief operating officer of SNBL. “We remain confident SNBL is performing at a level that will produce high-quality, GLP-compliant work.” The warning letter specified nine items, of which seven have been completely resolved. The remaining two items req...